08:55 AM EDT, 07/22/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) said Tuesday it entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital (OWL), which will be primarily used to advance its therapeutics pipeline for liver disease.

The financing consists of a $350 million initial term loan that was partly used to refinance Madrigal's existing $115 million senior secured debt, the company said.

The agreement also includes up to an additional $150 million, available in multiple draws through December 2027, as well as the possibility for up to $250 million in additional credit facilities to support further expansion of the company's pipeline, Madrigal said.